培美曲塞二钠联合卡铂治疗老年中晚期非小细胞肺癌的临床探讨

摘要

Objective To study the clinical effect on elderly patients with middle-late stage non-small cell lung cancer treated with pemetrexed disodium and carboplatin.Methods From September 2012 to December 2014,100 elderly patients with middle-late stage non-small cell lung cancer were collected and randomly divided into observation group and control group with 50 cases in each group.Observation group was treated with pemetrexed disodium and carboplatin,while control group was treated with gemcitabine and carboplatin.Results The total effective rate of observation group was 56％,that of control group was 50％,without statistically significant difference (P＞0.05).After treatment,a total of 9 patients of observation group had adverse reactions of hematologic toxicity,5 patients had adverse reactions of digestive tract toxicity,3 patients had adverse reactions of biochemical toxicity,and 4 patients had other adverse reactions,all significantly less than those of control group (P＜0.05).The time of tumor progression (TTP) of observation group was (6.9±1.1) months,the median survival time (MST) was (8.6±1.3) months,and 1 year survival rate was 52.6％,with statistically significant differences compared with control group (P＜0.05).Conclusion Elderly patients with middle-late stage non-small cell lung cancer treated with pemetrexed disodium and carboplatin have fewer adverse reactions and longer survival time.%目的 探讨培美曲塞二钠联合卡铂治疗老年中晚期非小细胞肺癌的临床效果.方法 采集我院2012年9月至2014年12月收治的100例中晚期非小细胞肺癌患者,将所有患者随机分为观察组和对照组,每组50例.观察组患者采用培美曲塞二钠联合卡铂治疗,对照组患者采用吉西他滨联合卡铂治疗.结果 观察组患者的总有效率为56％,对照组患者的总有效率为50％,两组比较差异无统计学意义(P＞0.05).观察组患者治疗后血液学毒性不良反应共9例,消化道毒性不良反应共5例,生化毒性不良反应共3例,其他不良反应共4例,均明显少于对照组(P＜0.05).观察组患者的肿瘤进展时间(TTP)为(6.9±1.1)个月,中位生存时间(MST)为(8.6±1.3)个月,1年生存率为52.6％,与对照组比较均有统计学差异(P＜0.05).结论 培美曲塞二钠联合卡铂治疗老年中晚期非小细胞肺癌不良反应少,生存时间长.